Eniluracil is under clinical development by Processa Pharmaceuticals and currently in the Phase I and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Eniluracil’s likelihood of approval (LoA) and phase transition for Gastrointestinal Tumor took place on 03 Nov 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Eniluracil Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Eniluracil overview

Eniluracil is under development for the treatment of metastatic breast cancer, metastatic colorectal cancer and pancreatic cancer. The drug candidate is administered through oral route. It targets dihydropyrimidine dehydrogenase. It was also under development for hepatocellular carcinoma , non-small cell lung carcinoma, gastric cancer, cervical cancer, prostate cancer.

Processa Pharmaceuticals overview

Processa Pharmaceuticals, formerly Heatwurx, is a biopharmaceutical company which develops and commercializes drugs for the treatment of skin diseases and various cancer types. It is investigating its lead product candidate: PCS499 to treat necrobiosis lipoidica (NL), a chronic, disfiguring skin disorder; and to treat the side effects of radiation in patients with head and neck cancer. The PCS499 holds Orphan Drug designation for the treatment of NL. The company is evaluating PCS100, an anti-fibrotic and anti-inflammatory drug against idiopathic pulmonary fibrosis (IPF) and primary glomerulonephritis. It operates in the US. Processa Pharmaceuticals is headquartered in Baltimore, Maryland, the US.

Quick View Eniluracil LOA Data

Report Segments
  • Innovator
Drug Name
  • Eniluracil
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.